We observed in this study that treatment with HDACi and docetaxel resulted in increased migratory behavior in both AR-positive and AR-negative prostate cancer cells, indicating that these effects on cell migration in prostate cancer cells are not limited to only anti-androgens. Here, AR is linked to prostate carcinoma.